Myriad Genetics (MYGN) Depreciation and Depletion (2014 - 2026)

Myriad Genetics (MYGN) has 13 years of Depreciation and Depletion data on file, last reported at $4.7 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $4.7 million, down 7.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.1 million (down 2.05% YoY), and the FY2025 annual result was $19.5 million, changed 0.0% from the prior year.
• Depreciation and Depletion steadied at $4.7 million in Q1 2026 per MYGN's latest filing, from $4.7 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $8.7 million in Q1 2023 and troughed at $2.7 million in Q2 2023.
• A 5-year average of $4.4 million and a median of $4.7 million in 2025 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2023 and 2024: Depreciation and Depletion jumped 210.71% in 2023, then tumbled 43.68% in 2024.
• A 5-year view of Depreciation and Depletion shows it stood at $3.1 million in 2022, then surged by 38.71% to $4.3 million in 2023, then advanced by 16.28% to $5.0 million in 2024, then retreated by 6.0% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
• Business Quant data shows MYGN's Depreciation and Depletion at $4.7 million in Q1 2026, $4.7 million in Q4 2025, and $4.8 million in Q3 2025.